Biotech Values

[DewDiligence]

OXGN—I finally got to listen to the CC from 9/30/15 on the planned phase-3 program for CA4P. (Listening to the CC felt like being in a circa-2004 time warp.)

By OXGN’s own admission, the phase-2 portion of the phase-2/3 trial in second-line ovarian cancer has only 60-70% statistical power to detect the expected delta between the CA4P arm and the SoC arm. In other words, even if CA4P works in this setting the way OXGN thinks it will, there’s a 30-40% chance that the phase-3 portion of the ovarian trial will not be conducted. This is the company's lead program.